Core Viewpoint - LSI Industries Inc. has announced the pricing of its underwritten public offering of common stock, aiming to raise approximately $90 million to support its growth and acquisition strategy, including the acquisition of Royston Group [1][2][3] Group 1: Offering Details - The company is offering 4,600,000 shares at a public offering price of $19.75 per share, with gross proceeds expected to be around $90 million before deductions [2] - LSI has granted underwriters a 30-day option to purchase an additional 690,000 shares at the same public offering price [2] - The offering is anticipated to close on or about March 2, 2026, pending customary closing conditions [2] Group 2: Use of Proceeds - The net proceeds from the offering will be used for several purposes, including a portion of the purchase price for the Royston Group acquisition, repayment of borrowings under a proposed Senior Secured Credit Facility, and general working capital [3] Group 3: Company Overview - LSI Industries is a publicly held company based in Cincinnati, traded on NASDAQ under the symbol LYTS, specializing in commercial lighting and display solutions [7] - The company manufactures a range of products, including non-residential indoor and outdoor lighting, print graphics, and digital graphics, employing approximately 2,000 people across 18 manufacturing plants in the U.S. and Canada [7]

Group 1 - Avalon GloboCare Corp. has entered into definitive agreements for the issuance and sale of 6,372,550 shares of common stock and associated warrants at a purchase price of $0.51 per share [1][3] - The offering is expected to generate approximately $3.25 million in gross proceeds before fees and expenses, with potential additional proceeds of about $6.5 million from the warrants if fully exercised [3] - The Series A-1 warrants will expire five years from stockholder approval, while the Series A-2 warrants will expire eighteen months from stockholder approval [1] Group 2 - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2] - The securities are offered in a private placement under Section 4(a)(2) of the Securities Act and are not registered under the Act or applicable state laws, being available only to accredited investors [4] - The company plans to use the net proceeds for repayment of outstanding debt and for working capital and general corporate purposes [3][4] Group 3 - Avalon GloboCare Corp. is focused on developing precision diagnostic consumer products and generative AI publishing and software [1][6] - The company is advancing AI systems through its subsidiary, Avalon Quantum AI LLC, and is also marketing the KetoAir™ breathalyzer device registered as a Class I medical device [6]

Enzo Villani, Executive Chairman and Chief Investment Officer of AlphaTON Capital By Exec Edge Research Staff AlphaTON Capital Corp. (ATON) has been assigned a $2 per share price target by broker H.C. Wainwright & Co., indicating a fivefold potential upside from current prices. “[W]e think the extraordinary compilation of integrated technology importantly presents a substantial opportunity for an enterprise within the Telegram messaging network serving one billion, billion with a “b,” users,” H.C. Wainw ...

Core Viewpoint - Addex Therapeutics has amended its At The Market Offering Agreement with H.C. Wainwright & Co. to allow for the sale of American Depositary Shares (ADSs) with an aggregate offering price of up to $3.3 million [1] Group 1: Offering Details - The amended ATM Agreement enables Addex to sell ADSs at its discretion through H.C. Wainwright & Co. [1] - H.C. Wainwright & Co. will sell the ADSs using methods permitted by law, including sales on The Nasdaq Capital Market [2] - The sales commission for H.C. Wainwright & Co. is set at three percent (3.0%) of the gross sales proceeds from any ADSs sold [2] Group 2: Company Background - Addex Therapeutics is focused on developing novel small molecule allosteric modulators for neurological disorders [5] - The lead drug candidate, dipraglurant, is being evaluated for brain injury recovery, including post-stroke and traumatic brain injury recovery [5] - Addex has partnerships for developing GABAB PAM drug candidates for substance use disorders and is advancing an independent GABAB PAM program for chronic cough [5] Group 3: Corporate Structure - Addex holds a 20% equity interest in Neurosterix US Holdings LLC, which is advancing allosteric modulator programs for various mental health disorders [5] - The company has also invested in Stalicla, a private Swiss company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders [5] Group 4: Stock Information - Addex shares are listed on the SIX Swiss Exchange and NASDAQ Capital Market under the ticker symbol "ADXN" [6]

This pop can be credited to the company's decision to acquire Ask Sage, a generative AI platform "for secure distribution of AI models and agentic AI capabilities, built specifically for defense and national security agencies and other highly regulated sectors." BigBear.ai will pay $250 million for this acquisition, and it looks like this move indeed has the ability to boost the company's falling growth.Its gross margin fell by 3.5 percentage points year over year due to the loss of higher-margin contracts. ...

Core Viewpoint - Predictive Oncology is advancing its artificial intelligence and machine learning initiatives to enhance early drug discovery and drug development for cancer patients globally, while also implementing a digital asset treasury strategy involving ATH tokens from the Aethir ecosystem [1][14]. Transaction Overview - The company plans to raise approximately $344.4 million through two private investment transactions, which include the sale of about 66.7 million shares at a price of $0.7751 per share, generating around $51.7 million in cash proceeds, and pre-funded warrants for up to 223.6 million shares, valued at approximately $292.7 million in notional value [2]. - The transactions are expected to close around October 2, 2025, pending customary closing conditions [2]. Use of Proceeds - The funds from the private placements will primarily be used to support the digital asset treasury strategy, acquire ATH tokens in the open market, and for general corporate purposes [3]. Aethir Infrastructure - Aethir operates a large decentralized GPU network, providing AI infrastructure with cost savings of approximately 40-80% compared to traditional providers, and offers rapid deployment of services [4]. - The network consists of 435,000 GPU containers across over 200 locations in 93 countries, facilitating global access to Nvidia GPUs-as-a-Service [4]. Digital Asset Strategy - The digital asset treasury will manage ATH tokens, leveraging Aethir's model to enhance the deployment and monetization of compute resources across various enterprise sectors [5]. - For every ATH token purchased, the DCI Foundation will grant an additional 20% of the tokens to the company, linking ATH token value to real-world infrastructure demand [6]. Strategic Partnership - The partnership with Aethir is viewed as a significant opportunity for Predictive Oncology to solidify its core business and explore growth through the digital asset treasury strategy [7]. - The company aims to establish the world's first Strategic Compute Reserve, functioning as an operator within the Aethir ecosystem [8]. Advisory and Legal Support - DNA Holdings Venture, Inc. is acting as the strategic advisor for the digital asset treasury, while H.C. Wainwright & Co. serves as the exclusive placement agent for the private placements [9].

Group 1 - Cocrystal Pharma, Inc. has entered into definitive agreements for the purchase and sale of 2,764,710 shares of its common stock at a price of $1.70 per share, with gross proceeds expected to be approximately $4.7 million [1][3] - In a concurrent private placement, the company will issue unregistered warrants to purchase up to 5,529,420 shares of common stock at an exercise price of $1.50 per share, potentially adding approximately $8.3 million in gross proceeds if fully exercised [1][3] - The offering is expected to close on or about September 15, 2025, subject to customary closing conditions [1] Group 2 - H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering [2] - The net proceeds from the offering are intended for working capital and general corporate purposes [3] Group 3 - The common stock is being offered under a "shelf" registration statement that was declared effective by the SEC on May 26, 2023 [4] - The unregistered warrants are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and have not been registered under the Securities Act [5] Group 4 - Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on developing innovative antiviral treatments for diseases such as influenza, viral gastroenteritis, COVID, and hepatitis [7]

Company Overview - Motorsport Games Inc. is a racing game developer, publisher, and esports ecosystem provider, focusing on official motorsport racing series [4] - The company is known for its innovative video games and engaging esports competitions, aiming to create racing games that closely resemble reality [4] - Motorsport Games holds licenses for iconic racing series such as the 24 Hours of Le Mans and the FIA World Endurance Championship, with recent releases including Le Mans Ultimate Version 1.0 [4] Upcoming Events - The CEO Stephen Hood and CFO Stanley Beckley will present and host one-on-one meetings with investors at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City [1][7] - Investors can schedule one-on-one meetings with the executives by contacting the company via email [2] Investor Relations - A replay of the conference webcast will be available on the investor section of Motorsport Games' website [2] - The company utilizes various channels, including its investor relations website and social media, to communicate material financial information to investors [6]

Company Overview - Algorhythm Holdings, Inc. is an AI technology holding company focused on providing AI-powered transportation solutions through its primary business unit, SemiCab [4] - SemiCab aims to optimize truck utilization, reduce empty miles, and deliver measurable efficiencies for clients in the U.S. and India [4] Business Model and Technology - SemiCab's Collaborative Transportation Platform is AI-enabled and cloud-based, designed to predict and optimize millions of loads and hundreds of thousands of trucks [5] - The platform utilizes real-time data from API-based load tendering and integrates with TMS and ELD partners to enhance collaboration among manufacturers, retailers, distributors, and carriers [5] - The AI platform allows shippers to pay less while enabling carriers to earn more without requiring operational changes [5] Upcoming Events - Gary Atkinson, the CEO of Algorhythm Holdings, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8–10, 2025, in New York City [1] - A presentation by Mr. Atkinson will be available via webcast for conference attendees, with on-demand access starting September 5 at 7:00 AM ET [2] - One-on-one meetings with Mr. Atkinson can be scheduled by registered conference attendees through the conference scheduling platform [3]

Company Overview - Psyence Biomedical Ltd. is a biopharmaceutical company focused on developing nature-derived psilocybin and ibogaine therapies for unmet mental health needs [5] - It is the first life sciences biotechnology company specializing in psychedelic-based therapeutics to be listed on Nasdaq [5] - The company aims to address unmet mental health needs, particularly in palliative care, through an evidence-based approach [5] Upcoming Events - Psyence BioMed will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8–10, 2025 [1][9] - Dr. Neil Maresky, CEO of Psyence BioMed, will discuss the company's business strategy and pipeline during the conference [2] - A webinar for investors and shareholders is scheduled for September 16, 2025, featuring members of the Scientific Advisory Board [4] Strategic Positioning - The company emphasizes its unique operational footprint in Africa and commitment to clinical excellence as key differentiators in the psychedelic medicine sector [3] - Psyence BioMed aims to engage with global investors to highlight its differentiated approach in the industry [3]